抗体药物偶联物
其他题名Antibody-Drug Conjugates
曹刚1; 黄祚刚1; 程杰飞1; 姜标1
2014
发表期刊Prog. Chem.
卷号26期号:2-3页码:467-477
其他摘要Over 35 monoclonal antibody drugs have been marketed since the approval of first monoclonal antibody drug in 1986, making the antibody drug development one of the most exciting fields. Antibody-drug conjugate (ADC), which combines a monoclonal antibody (mAb) with a cytotoxic (drug) molecule through a linker and thereby the name, is a new class of highly potent biopharmaceutical drugs designed as a targeted therapy. ADC takes advantage of the high binding specificity of mAbs and superior efficacy of cytotoxic molecules, while avoiding the dose-limiting toxicity of cytotoxic molecules. The first ADC, Mylotarg, was approved in 2000, which was late withdrawn by the manufacture due to the lack of appropriate stability of the linker. So far, there are two approved ADCs in the market for cancer therapy and over twenty ADCs in various stages of clinical trials. Creating a successful antibody drug conjugate requires careful selection of the drug, antibody and linker. Linker has a great influence on a conjugate' s biological characteristics, such as stability in circulation and drug release at the target site. ADCs have been proven to be effective weapons against cancers and will certainly become useful therapeutics against other diseases.
学科领域天然产物有机化学
DOI10.7536/PC130650
URL查看原文
收录类别SCI
语种中文
引用统计
文献类型期刊论文
条目标识符http://ir.sioc.ac.cn/handle/331003/38978
专题中科院天然产物有机化学重点实验室
通讯作者程杰飞; 姜标
作者单位1.中科院上海高等研究院
2.大冢(上海)药物研究开发有限公司
3.中科院上海有机化学研究所
4.上海科技大学
推荐引用方式
GB/T 7714
曹刚,黄祚刚,程杰飞,等. 抗体药物偶联物[J]. Prog. Chem.,2014,26(2-3):467-477.
APA 曹刚,黄祚刚,程杰飞,&姜标.(2014).抗体药物偶联物.Prog. Chem.,26(2-3),467-477.
MLA 曹刚,et al."抗体药物偶联物".Prog. Chem. 26.2-3(2014):467-477.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
2014154.pdf(1458KB)期刊论文作者接受稿开放获取CC BY-NC-SA请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[曹刚]的文章
[黄祚刚]的文章
[程杰飞]的文章
百度学术
百度学术中相似的文章
[曹刚]的文章
[黄祚刚]的文章
[程杰飞]的文章
必应学术
必应学术中相似的文章
[曹刚]的文章
[黄祚刚]的文章
[程杰飞]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。